Kutani neželjeni efekti erlotiniba - prikaz slučaja
Erlotinib prikaz slučaja
Sažetak
Erlotinib je antineoplastični lijek koji se koristi u liječenju nemikrocelularnog karcinoma pluća i karcinoma pankreasa. On je snažani, selektivni inhibitor tirozin kinaze, receptora za epidermalni faktor rasta (EGFR). Kod njegove upotrebe opisane su brojne nuspojave na koži poput akneiformne erupcije, kseroze, telangiektazija, promjene na kosi i noktima. Ovde dajemo prikazuje slučaj 70-godišnje pacijentice kod koje su se nesvakidašnje nuspojave na koži razvile nakon 6 godina liječenja erlotinibom.
Reference
1. Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem 2020;20(10):815-34.
2. Chen KL, Lin CC, Cho YT, Yang CW, Sheen YS, Tsai HE, et al. Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer. JAMA Dermatol 2016;152(3):340-2.
3. Julian I, Iwamoto T. Investigation of biomarkers and handling strategy of erlotinib-induced skin rash in rats. Biol Pharm Bull 2021;44(8):1050-9.
4. Carlesimo M, Pigliacelli F, D'Arino A, Caro G, Fortuna MC, Rossi A. Dermatologic management of oncotherapy side effects: a proposed algorithm. J Cosmet Dermatol 2021;20(2):429-36.
5. Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 2013;69(3):463-72.
6. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015;72(2):203-18.
7. Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011;18(3):126-38.
8. Saif MW, Merikas I, Tsimboukis S, Syrigos K. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008;9(3):267-74.
9. Patrizi A, Bianchi F, Neri I. Rosaceiform eruption induced by erlotinib. Dermatol Ther 2008;21 Suppl 2:S43-5.
10. Komiya N, Takahashi K, Kato G, Kubota M, Tashiro H, Nakashima C, et al. Acute generalized exanthematous pustulosis caused by erlotinib in a patient with lung cancer. Case Rep Oncol 2021;14(1):599-603.
11. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17(11 Suppl 12):23-8.
12. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13(13):3913-21.
13. Julian I, Iwamoto T. Investigation of biomarkers and handling strategy of erlotinib-induced skin rash in rats. Biol Pharm Bull 2021;44(8):1050-9.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).